Drug-related sarcopenia as a secondary sarcopenia.
adverse drug reactions
drug-related sarcopenia
muscle wasting
sarcopenia
Journal
Geriatrics & gerontology international
ISSN: 1447-0594
Titre abrégé: Geriatr Gerontol Int
Pays: Japan
ID NLM: 101135738
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
received:
06
11
2023
accepted:
24
11
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
30
12
2023
Statut:
aheadofprint
Résumé
Sarcopenia has a significant impact on falls, physical function, activities of daily living, and quality of life in older adults, and its prevention and treatment are becoming increasingly important as the global population ages. In addition to primary age-related sarcopenia, activity-related sarcopenia, disease-related sarcopenia, and nutrition-related sarcopenia have been proposed as secondary sarcopenia. Polypharmacy and potentially inappropriate medication based on multiple diseases cause health problems in older patients. In some cases, drugs used for therapeutic or preventive purposes act on skeletal muscle as adverse drug reactions and induce sarcopenia. Although sarcopenia caused by these adverse drug reactions may be more common in older patients, in particular those taking many medications, drug-related sarcopenia has not yet received much attention. This review summarizes drugs that may induce sarcopenia and emphasizes the importance of drug-related sarcopenia as a secondary sarcopenia. Geriatr Gerontol Int 2023; ••: ••-••.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 Japan Geriatrics Society.
Références
Rosenberg IH. Summary comments. Am J Clin Nutr 1989; 50: 1231-1233.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010; 39: 412-423.
Janssen L, Allard NAE, Saris CGJ, Keijer J, Hopman MTE, Timmers S. Muscle toxicity of drugs: when drugs turn physiology into pathophysiology. Physiol Rev 2020; 100: 633-672.
Kuzuya M. Effect of drugs on nutritional status and drug-nutrition interactions in older patients. Geriatr Gerontol Int 2023; 23: 465-477.
Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res 2023; 118: 3288-3304.
Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014; 168: 6-15.
Goodman CA, Pol D, Zacharewicz E et al. Statin-induced increases in atrophy gene expression occur independently of changes in PGC1α protein and mitochondrial content. PloS One 2015; 10: e0128398.
Lee DS, Markwardt S, Goeres L et al. Statins and physical activity in older men: the osteoporotic fractures in men study. JAMA Intern Med 2014; 174: 1263-12670.
Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012; 40: 188-194.
Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol 2010; 21: 324-328.
Matsumoto A, Yoshimura Y, Nagano F et al. Statin use impairs muscle strength recovery in post-stroke patients with sarcopenia. Geriatr Gerontol Int 2023; 23: 676-683. https://doi.org/10.1111/ggi.14646.
Lindström I, Protto S, Khan N, Väärämäki S, Oksala N, Hernesniemi J. Statin use, development of sarcopenia, and long-term survival after endovascular aortic repair. J Vasc Surg 2021; 74: 1651-1658.
Lin MH, Chiu SY, Chang PH, Lai YL, Chen PC, Ho WC. Hyperlipidemia and statins use for the risk of new diagnosed sarcopenia in patients with chronic kidney: a population-based study. Int J Environ Res Public Health 2020; 17: 1494.
Veddeng S, Madland H, Molden E, Wyller TB, Romskaug R. Association between statin use and physical performance in home-dwelling older patients receiving polypharmacy: cross-sectional study. BMC Geriatr 2022; 22: 242.
van Boheemen L, Tett SE, Sohl E, Hugtenburg JG, van Schoor NM, Peeters GMEE. Associations between statin use and physical function in older adults from The Netherlands and Australia: longitudinal aging study Amsterdam and Australian longitudinal study on Women's health. Drugs Aging 2016; 33: 437-445.
Parker BA, Capizzi JA, Grimaldi AS et al. Effect of statins on skeletal muscle function. Circulation 2013; 127: 96-103.
Anagnostis P, Gkekas NK, Achilla C et al. Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis. Calcif Tissue Int 2020; 107: 453-463.
Pollakova D, Tubili C, Di Folco U et al. Muscular involvement in long-term type 1 diabetes: does it represent an underestimated complication? Nutrition 2023; 112: 112060.
Witham MD, Granic A, Pearson E, Robinson SM, Sayer AA. Repurposing drugs for diabetes mellitus as potential pharmacological treatments for sarcopenia - a narrative review. Drugs Aging 2023; 40: 703-719.
Massimino E, Izzo A, Riccardi G, Della Pepa G. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms. Cell 2021; 10: 1958.
Mele A, Calzolaro S, Cannone G, Cetrone M, Conte D, Tricarico D. Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol Res Perspect 2014; 2: e00028.
Wu CN, Tien KJ. The impact of antidiabetic agents on sarcopenia in type 2 diabetes: a literature review. J Diabetes Res 2020; 2020: 9368583.
Mellen RH, Girotto OS, Marques EB et al. Insights into pathogenesis, nutritional and drug approach in sarcopenia: a systematic review. Biomedicine 2023; 11: 136.
Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of glucagon-like Peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab 2019; 34: 247-262.
Zhang S, Qi Z, Wang Y, Song D, Zhu D. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front Endocrinol 2023; 14: 1203666.
Xia C, Han Y, Yin C et al. Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Front Endocrinol 2023; 14: 1220516.
Pedrosa MB, Barbosa S, Vitorino R et al. Chemotherapy-induced molecular changes in skeletal muscle. Biomedicine 2023; 11: 905.
Bozzetti F. Chemotherapy-induced sarcopenia. Curr Treat Options Oncol 2020; 21: 7.
Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010; 28: 1054-1060.
Garcia JM, Scherer T, Chen JA et al. Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology 2013; 154: 3118-3129.
Pin F, Barreto R, Couch ME, Bonetto A, O'Connell TM. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J Cachexia Sarcopenia Muscle 2019; 10: 140-154.
Campelj DG, Goodman CA, Rybalka E. Chemotherapy-induced myopathy: the dark side of the cachexia sphere. Cancers 2021; 13: 3615.
Farina A, Villagrán-García M, Honnorat J. Neurological adverse events of immune checkpoint inhibitors: an update of clinical presentations, diagnosis, and management. Rev Neurol 2023; 179: 506-515.
Dang QM, Watanabe R, Shiomi M et al. Rheumatic immune-related adverse events due to immune checkpoint inhibitors-a 2023 update. Int J Mol Sci 2023; 24: 5643.
Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013; 45: 2163-2172.
Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011; 78: 41-44.
Surmachevska N, Tiwari V. Corticosteroid Induced Myopathy. Treasure Island (FL): StatPearls, 2023.
Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. J Am Acad Dermatol 2017; 76: 201-207.
Tam K, Wong-Pack M, Liu T et al. Risk factors and clinical outcomes associated with sarcopenia in rheumatoid arthritis: a systematic review and meta-analysis. J Clin Rheumatol 2023. https://doi.org/10.1097/RHU.0000000000001980 Publish Ahead of Print.
Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008; 197: 1-10.
Macedo AG, Almeida TAF, Massini DA, de Paula VF, de Oliveira DM, Pessôa Filho DM. Effects of exercise training on glucocorticoid-induced muscle atrophy: literature review. Steroids 2023; 195: 109240.
Shigehara K, Kato Y, Izumi K, Mizokami A. Relationship between testosterone and sarcopenia in older-adult men: a narrative review. J Clin Med 2022; 11: 6202.
Lunenfeld B, Mskhalaya G, Zitzmann M et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male 2021; 24: 119-138.
Owen PJ, Daly RM, Livingston PM, Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis 2017; 20: 137-145.
Cheung AS, Gray H, Schache AG et al. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study. J Cachexia Sarcopenia Muscle 2017; 8: 102-112.
Smith MR, Saad F, Egerdie B et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 2012; 30: 3271-3276.
Shao W, Zhang H, Qi H, Zhang Y. The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: an update systematic review and meta-analysis. PloS One 2022; 17: e0263918.
Biguetti CC, Junior JFS, Fiedler MW, Marrelli MT, Brotto M. The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis. Sci Rep 2021; 11: 6589.
Andonian BJ, Huffman KM. Skeletal muscle disease in rheumatoid arthritis: the center of cardiometabolic comorbidities? Curr Opin Rheumatol 2020; 32: 297-306.
Letarouilly JG, Flipo RM, Cortet B, Tournadre A, Paccou J. Body composition in patients with rheumatoid arthritis: a narrative literature review. Ther Adv Musculoskelet Dis 2021; 13: 1759720X211015006.
Dao T, Kirk B, Phu S, Vogrin S, Duque G. Prevalence of sarcopenia and its association with antirheumatic drugs in middle-aged and older adults with rheumatoid arthritis: a systematic review and meta-analysis. Calcif Tissue Int 2021; 109: 475-489.
Yamada Y, Tada M, Mandai K, Hidaka N, Inui K, Nakamura H. Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol 2020; 39: 1757-1764.
Ben Tekaya A, Mehmli T, Ben Sassi M et al. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2023; 42: 979-997.
Wilbur K, Makowsky M. Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004; 24: 1784-1792.
Kuncl RW, Bilak MM, Craig SW, Adams R. Exocytotic “constipation” is a mechanism of tubulin/lysosomal interaction in colchicine myopathy. Exp Cell Res 2003; 285: 196-207.
Xie G, Jin H, Mikhail H et al. Autophagy in sarcopenia: possible mechanisms and novel therapies. Biomed Pharmacother 2023; 165: 115147.
Chen W, Chen Y, Liu Y, Wang X. Autophagy in muscle regeneration: potential therapies for myopathies. J Cachexia Sarcopenia Muscle 2022; 13: 1673-1685.
Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322: 1098-1105.
SeyedAlinaghi S, Ghayomzadeh M, Mirzapour P et al. A systematic review of sarcopenia prevalence and associated factors in people living with human immunodeficiency virus. J Cachexia Sarcopenia Muscle 2023; 14: 1168-1182.
Zhang Z, Lin Q, Xu Y et al. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males. Arch Osteoporos 2023; 18: 48.
Park SH, Park KS, Kim NH, Cho JY, Koh MS, Lee JH. Clevudine induced mitochondrial myopathy. J Korean Med Sci 2017; 32: 1857-1860.
Prokopidis K, Giannos P, Reginster JY et al. Special interest group in systematic reviews and meta-analyses and the task force on pharmaceutical strategy of the European Geriatric Medicine Society (EuGMS). Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2023; 14: 671-683.
Tanaka T, Akishita M, Kojima T, Son BK, Iijima K. Polypharmacy with potentially inappropriate medications as a risk factor of new onset sarcopenia among community-dwelling Japanese older adults: a 9-year Kashiwa cohort study. BMC Geriatr 2023; 23: 390.
Matsumoto A, Yoshimura Y, Nagano F et al. Potentially inappropriate medications are negatively associated with functional recovery in patients with sarcopenia after stroke. Aging Clin Exp Res 2022; 34: 2845-2855.
Mandai S, Furukawa S, Kodaka M et al. Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Sci Rep 2017; 7: 46369.
Nakano I, Tsuda M, Kinugawa S et al. Loop diuretic use is associated with skeletal muscle wasting in patients with heart failure. J Cardiol 2020; 76: 109-114.
Hanai T, Shiraki M, Miwa T et al. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatol Res 2019; 49: 82-95.
Ishikawa S, Naito S, Iimori S et al. Loop diuretics are associated with greater risk of sarcopenia in patients with non-dialysis-dependent chronic kidney disease. PloS One 2018; 13: e0192990.
Zhou RP, Chen Y, Wei X et al. Novel insights into ferroptosis: implications for age-related diseases. Theranostics 2020; 10: 11976-11997.
Alves FM, Ayton S, Bush AI, Lynch GS, Koopman R. Age-related changes in skeletal muscle iron homeostasis. J Gerontol A Biol Sci Med Sci 2023; 78: 16-24.
Xu J, Knutson MD, Carter CS, Leeuwenburgh C. Iron accumulation with age, oxidative stress and functional decline. PloS One 2008; 3: e2865.
Hofer T, Marzetti E, Xu J et al. Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy. Exp Gerontol 2008; 43: 563-570.
DeRuisseau KC, Park YM, DeRuisseau LR et al. Aging-related changes in the iron status of skeletal muscle. Exp Gerontol 2013; 48: 1294-1302.
Picca A, Mankowski RT, Kamenov G et al. Advanced age is associated with iron Dyshomeostasis and mitochondrial DNA damage in human skeletal muscle. Cell 2019; 8: 1525.
Ikeda Y, Imao M, Satoh A et al. Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway. J Trace Elem Med Biol 2016; 35: 66-76.
Wyart E, Hsu MY, Sartori R et al. Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia. EMBO Rep 2022; 23: e53746.
Vinke JSJ, Gorter AR, Eisenga MF et al. Iron deficiency is related to lower muscle mass in community-dwelling individuals and impairs myoblast proliferation. J Cachexia Sarcopenia Muscle 2023; 14: 1865-1879.
Chen Z, Chen J, Song C, Sun J, Liu W. Association between serum iron status and muscle mass in adults: results from NHANES 2015-2018. Front Nutr 2022; 9: 941093.
Scherbakov N, Sandek A, Valentova M et al. Iron deficiency and reduced muscle strength in patients with acute and chronic ischemic stroke. J Clin Med 2022; 11: 595.
Vill K, Müller-Felber W, Teusch V et al. Proximal muscular atrophy and weakness: an unusual adverse effect of deferasirox iron chelation therapy. Neuromuscul Disord 2016; 26: 322-325.
Malla J, Zahra A, Venugopal S et al. What role do inflammatory cytokines play in cancer cachexia? Cureus 2022; 14: e26798.
Bolko L, Jiang W, Tawara N et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol 2021; 31: e12955.
Kim KH, Joo DJ, Lee YH et al. Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. Dig Liver Dis 2020; 52: 1338-1345.
Bellaver P, Schaeffer AF, Leitao CB, Rech TH, Nedel WL. Association between neuromuscular blocking agents and the development of Intensive Care Unit-Acquired Weakness (ICU-AW): a systematic review with meta-analysis and trial sequential analysis. Anaesth Crit Care Pain Med 2023; 42: 101202.
Yang Z, Wang X, Wang F, Peng Z, Fan Y. A systematic review and meta-analysis of risk factors for intensive care unit acquired weakness. Medicine 2022; 101: e31405.